Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MBOAT4 | Q96T53 | 5/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | USP7 | Q93009 | 1/20 | 0.52 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23544232 | 1.00 | NOS2 (0.54) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 | |
| SCHEMBL20860795 | 1.00 | NOS2 (0.54) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 | |
| SCHEMBL22053193 | 1.00 | NOS2 (0.54) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 | |
| SCHEMBL22293727 | 1.00 | NOS2 (0.54) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 | |
| SCHEMBL18972906 | 0.89 | NOS2 (0.56) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 | |
| SCHEMBL23758922 | 0.87 | NOS2 (0.54) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 | |
| SCHEMBL18923293 | 0.87 | NOS2 (0.54) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 | |
| SCHEMBL19491757 | 0.86 | NOS2 (0.46) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 | |
| SCHEMBL20925563 | 0.85 | NOS2 (0.55) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 | |
| SCHEMBL23552904 | 0.85 | NOS2 (0.53) | NOS2CYP3A4CYP2C19KEAP1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20200289607-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9757359-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289607-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | FECH, KEAP1, NFE2L2 | NOS2 366/4885CYP3A4 2300/4885CYP2C19 1603/4885 |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885CYP3A4 752/4885CYP2C19 1399/4885 |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | KEAP1, NFE2L2, TFAM | NOS2 540/4885CYP3A4 4327/4885CYP2C19 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.